The CDC recommends an updated 2024-2025 COVID-19 vaccine as authorized or approved by the FDA in persons aged 6 months and older.1

Easy for you, easy on them

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) pairs protection against circulating variants with manageable common side effects in a convenient prefilled syringe2,3*

*In clinical trials, most side effects were mild to moderate and of short duration.3

For representation purposes only. Actual size, packaging, and appearance may differ.

Staying up to date with COVID-19 vaccines is the best way to help keep your patients protected from COVID-19.4

Offer your patients a non-mRNA, protein-based alternative this season2,5

The effectiveness of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) is based on the effectiveness of the Novavax COVID-19 vaccine (original monovalent) and the immunogenicity of the monovalent vaccine (Omicron BA.1) and the monovalent vaccine (Omicron BA.5).2

COVID‑19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses its spike protein to bind to an ACE2 receptor on the airway epithelial cell and enters the cell.

This spike protein is the target of many vaccines that work in different ways allowing the immune system to build a defense against the virus.

Novavax COVID‑19 Vaccine, Adjuvanted, is a protein subunit vaccine produced using established technology that has also been used in some seasonal influenza, HPV and Hepatitis B vaccines. Novavax COVID‑19 Vaccine, Adjuvanted presents the spike protein part of the virus to the immune system. The vaccine is composed of multiple trimers of recombinant spike proteins, stabilized in the prefusion conformation, and bound to a polysorbate 80 core, and are highly immunogenic.

The vaccine is also formulated with Matrix-M, a proprietary adjuvant that includes saponin extracted from the bark of the Quillaja saponaria Molina tree.

Matrix-M enhances the magnitude of the immune response and promotes recruitment of various types of immune cells to draining lymph nodes, which may facilitate a more robust, long-lasting response.

Studies have shown that Novavax COVID‑19 Vaccine, Adjuvanted elicits an immune response, inducing both antibody-producing B-cells and multi-functional CD4+ and CD8+ T-cells. When challenged with the real virus, the antibodies block SARS-CoV-2 binding to the ACE receptor. Multifunctional T-cells produce multiple cytokines and are associated with an enhanced immune response to clear the virus. And effector memory T-cells target infected cells.

The Novavax COVID-19 vaccine is built on a well-established protein-based platform used in some vaccines for influenza, RSV, and hepatitis B.2,5-7

ACIP=Advisory Committee on Immunization Practices; HPV=human papillomavirus. 
*The Novavax COVID-19 vaccine may not protect all vaccine recipients.2

References: 1. Centers for Disease Control and Prevention. ACIP recommendations. https://www.cdc.gov/vaccines/acip/recommendations.html. Updated June 28, 2024. Accessed July 8, 2024. 2. Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) EUA Fact Sheet for Healthcare Providers. Novavax Inc.; August 2024. 3. Smith K, Hegazy K, et al. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials. Vaccine. 2023;41(26):3930-3936. 4. Centers for Disease Control and Prevention. Stay up to date with COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#print. Updated May 14, 2024. Accessed July 17, 2024. 5. Centers for Disease Control and Prevention. COVID-19 vaccine basics. https://www.cdc.gov/covid/vaccines/how-they-work.html. Updated July 12, 2024. Accessed July 18, 2024. 6. Cid R, Bolívar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. Biomolecules. 2021;11(8):1072. 7. Centers for Disease Control and Prevention. Healthcare providers: RSV vaccinations for adults 60 years of age and over. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html. Updated July 3, 2024. Accessed July 18, 2024.